Phase 1 trial of ASP3026

The first posting about this Phase 1 trial in was in 1-25-2011. The trial number is NCTO1284192. It was conducted at 6 hospitals.

On March 10, 2016 an article was published that said the dose escalation part of trial enrolled 33 patients, dose expansion cohort of 16 patients for a total of 46 patients. 16 patients were ALK + and Crizotinib resistant. Of these 50% had a partial response and 44% had stable disease for a disease control rate of 94%. The drug dose target ROS1 but they were not included in the expansion cohort.

main side effects were nausea, fatigue, and vomiting.

Previosly in May 2014, we had noted that Astellas was supposed to have discontinued research on ASP3026. It would appear they may have changed their minds.

This entry was posted in ASP3026 from Astellas, Lung cancer, Potential Treatments, Research. Bookmark the permalink.

Leave a Reply